GlassScriptPhysician profile
Amber D Long
NPI 1114491966
$4,231.68
in general payments reported to CMS, 2019-2025
23 companies · $978 in 2025
The $978 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $77.49 · 2022: $716 · 2023: $1,066 · 2024: $1,394 · 2025: $978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,078 · Education: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,077.95 |
| Education | $359.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $879.47 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Abbvie INC. | $644.54 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $556.11 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| Novartis Pharmaceuticals Corporation | $426.41 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $272.39 | 2023-2024 | Sotyktu |
| Janssen Biotech, INC. | $268.19 | 2022-2025 | Tremfya |
| Leo Pharma INC. | $237.19 | 2022-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $144.84 | 2022-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $124.82 | 2022-2025 | |
| Incyte Corporation | $113.79 | 2023 | Opzelura |
| Organogenesis INC. | $88.22 | 2024-2025 | Affinity, Cygnus Dual, Simplimax |
| Sanofi-Aventis U.S. LLC | $79.99 | 2024 | |
| Dermavant Sciences, INC. | $59.35 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $49.44 | 2023 | |
| Amgen INC. | $47.89 | 2024-2025 | Otezla, Otezla |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.94 | 2023-2024 | Spevigo |
| Galderma Laboratories, L.P. | $42.92 | 2025 | Nemluvio |
| Pfizer INC. | $39.66 | 2024 | |
| Janssen Scientific Affairs, LLC | $30.29 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.56 | 2023 | |
| Alnylam Pharmaceuticals INC. | $22.22 | 2024 | Givlaari |
| Biofrontera INC. | $18.34 | 2024 | Rhodoled Xl, Ameluz, Xepi |
| Ucb, INC. | $17.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.